Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Bought by Lincoln National Corp

Lincoln National Corp grew its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 17.6% during the fourth quarter, Holdings Channel.com reports. The firm owned 9,063 shares of the medical equipment provider’s stock after acquiring an additional 1,358 shares during the period. Lincoln National Corp’s holdings in Intuitive Surgical were worth $3,057,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its stake in Intuitive Surgical by 0.3% during the fourth quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 8,899 shares of the medical equipment provider’s stock worth $3,002,000 after purchasing an additional 27 shares during the period. Liberty Capital Management Inc. raised its stake in Intuitive Surgical by 3.8% during the fourth quarter. Liberty Capital Management Inc. now owns 815 shares of the medical equipment provider’s stock worth $275,000 after purchasing an additional 30 shares during the period. Miracle Mile Advisors LLC raised its stake in Intuitive Surgical by 2.3% during the fourth quarter. Miracle Mile Advisors LLC now owns 1,438 shares of the medical equipment provider’s stock worth $485,000 after purchasing an additional 32 shares during the period. Ausdal Financial Partners Inc. raised its stake in Intuitive Surgical by 1.5% during the fourth quarter. Ausdal Financial Partners Inc. now owns 2,192 shares of the medical equipment provider’s stock worth $739,000 after purchasing an additional 33 shares during the period. Finally, Venturi Wealth Management LLC raised its stake in Intuitive Surgical by 10.7% during the fourth quarter. Venturi Wealth Management LLC now owns 341 shares of the medical equipment provider’s stock worth $115,000 after purchasing an additional 33 shares during the period. 83.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ISRG has been the topic of a number of research reports. Piper Sandler raised their target price on shares of Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a research note on Friday, April 19th. Barclays raised their target price on shares of Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a research note on Thursday, January 25th. Wells Fargo & Company raised their target price on shares of Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a research note on Friday, January 19th. StockNews.com downgraded shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Finally, Mizuho raised their target price on shares of Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research note on Thursday, January 25th. Five investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $396.17.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock traded up $5.60 during trading hours on Tuesday, reaching $388.65. The company’s stock had a trading volume of 932,707 shares, compared to its average volume of 1,608,281. The company’s 50 day simple moving average is $385.29 and its 200 day simple moving average is $351.11. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $403.76. The stock has a market cap of $137.86 billion, a P/E ratio of 69.79, a price-to-earnings-growth ratio of 4.93 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. During the same period last year, the firm posted $1.00 EPS. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. On average, sell-side analysts predict that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Insider Activity at Intuitive Surgical

In related news, SVP Mark Brosius sold 196 shares of Intuitive Surgical stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total value of $78,400.00. Following the sale, the senior vice president now directly owns 1,842 shares in the company, valued at approximately $736,800. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Intuitive Surgical news, SVP Mark Brosius sold 196 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the sale, the senior vice president now directly owns 1,842 shares in the company, valued at approximately $736,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Alan J. Levy sold 2,000 shares of the business’s stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total transaction of $741,400.00. Following the sale, the director now owns 25,319 shares in the company, valued at $9,385,753.30. The disclosure for this sale can be found here. Insiders have sold a total of 228,637 shares of company stock worth $88,483,248 in the last ninety days. 0.80% of the stock is owned by insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.